Commentary: Should Cost and Comparative Value of Treatments Be Considered in Clinical Practice Guidelines?
- 1 November 2011
- journal article
- current clinical-issues
- Published by American Society of Clinical Oncology (ASCO) in Journal of Oncology Practice
- Vol. 7 (6) , 398-401
- https://doi.org/10.1200/jop.2011.000414
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline UpdateJournal of Clinical Oncology, 2011
- Bending the Cost Curve in Cancer CareNew England Journal of Medicine, 2011
- Cost–Utility Analysis of Palonosetron-Based Therapy in Preventing Emesis Among Breast Cancer PatientsJournal of Supportive Oncology, 2010
- How Medicare Could Use Comparative Effectiveness Research In Deciding On New Coverage And ReimbursementHealth Affairs, 2010
- Palonosetron compared to ondansetron in the prevention of chemotherapy-induced nausea and vomiting: Activity, safety, and cost-effectiveness evaluationJournal of Clinical Oncology, 2009
- Systematic Review: Reliability of Compendia Methods for Off-Label Oncology IndicationsAnnals of Internal Medicine, 2009
- Comparative Effectiveness Research in Oncology: The Need for Clarity, Transparency and VisionCancer Investigation, 2009
- Economic Evaluation of a New Antiemetic Drug - Palonosetron versus Ondansetron : Assessment of the Drug Price Ratio in Five European Countries.2005
- Economic Evaluation of a New Antiemetic Drug ??? Palonosetron versus OndansetronClinical Drug Investigation, 2005
- Outcomes of cancer treatment for technology assessment and cancer treatment guidelines. American Society of Clinical Oncology.Journal of Clinical Oncology, 1996